SCHEMBL3413345

SCHEMBL3413345

COc1ccc(-c2cccc(CC(=O)O)c2)cc1/C(C)=N/OCc1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
TBXA2R P21731 1/20 0.45
PTGER1 P34995 1/20 0.45
PPARG P37231 1/20 0.45
PPARA Q07869 1/20 0.45
PTPN11 Q06124 1/20 0.45
PTGDR2 Q9Y5Y4 4/20 0.41
S1PR1 P21453 2/20 0.41
GAA P10253 1/20 0.41
SHMT1 P34896 1/20 0.41
SHMT2 P34897 1/20 0.41
MRGPRX4 Q96LA9 2/20 0.40
PDE5A O76074 1/20 0.40
PDE1A P54750 1/20 0.40
PDE1B Q01064 1/20 0.40
PDE4D Q08499 1/20 0.40
PDE7A Q13946 1/20 0.40
PDE1C Q14123 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3413349 1.00 NR1H4 (0.48) NR1H4NPC1RAB9ATBXA2RPTGER1
SCHEMBL3416959 0.93 NR1H4 (0.46) NR1H4NPC1RAB9ATBXA2RPTGER1
SCHEMBL3416957 0.93 NR1H4 (0.46) NR1H4NPC1RAB9ATBXA2RPTGER1
SCHEMBL3418794 0.88 PPARG (0.47) NR1H4TBXA2RPPARGPPARAPTPN11
SCHEMBL3418793 0.88 PPARG (0.47) NR1H4TBXA2RPPARGPPARAPTPN11
SCHEMBL3414279 0.85 NPC1 (0.64) NPC1RAB9APPARGPPARAS1PR1
SCHEMBL3414272 0.85 NPC1 (0.64) NPC1RAB9APPARGPPARAS1PR1
SCHEMBL3416830 0.84 RXRA (0.46) NR1H4TBXA2RPPARAPTPN11PTGDR2
SCHEMBL3416833 0.84 RXRA (0.46) NR1H4TBXA2RPPARAPTPN11PTGDR2
SCHEMBL3413362 0.81 NR1H4 (0.54) NR1H4PTPN11GAAENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765950-B2 Reagents for biomolecular labeling, detection and quantification employing raman spectroscopy PURDUE RESEARCH FOUNDATION (US) 2014-07-01 US disclosed
US-7687664-B2 Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-30 US disclosed
US-7687664-B2 Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-30 US disclosed
US-7687664-B2 Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-30 US disclosed
US-20040214888-A1 Carboxylic acid derivative and medicine comprising salt or ester of the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-10-28 US disclosed
EP-1394147-A1 CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME Eisai Co., Ltd. (JP) 2004-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214888-A1 Carboxylic acid derivative and medicine comprising salt or ester of the same GPR119, NR3C1, INSR NR1H4 85/4885NPC1 424/4885RAB9A 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.